Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis

Amyotroph Lateral Scler. 2009;10 Suppl 2:118-23. doi: 10.3109/17482960903285951.

Abstract

Although the cyanobacteria/BMAA hypothesis of the cause of ALS and other age-related neurodegenerative diseases remains to be proven, it is not too early to ask whether treatment would be possible if the hypothesis were correct. This paper reviews the possible ways that chronic BMAA neurotoxicity could be prevented or treated.

Publication types

  • Review

MeSH terms

  • Amino Acids / therapeutic use
  • Amino Acids, Diamino / analysis
  • Amino Acids, Diamino / metabolism
  • Amino Acids, Diamino / toxicity*
  • Amino Acids, Dicarboxylic / analysis
  • Amino Acids, Dicarboxylic / metabolism
  • Amino Acids, Dicarboxylic / toxicity*
  • Amino Acyl-tRNA Synthetases / antagonists & inhibitors
  • Amino Acyl-tRNA Synthetases / drug effects
  • Amyotrophic Lateral Sclerosis / chemically induced*
  • Amyotrophic Lateral Sclerosis / diagnosis
  • Amyotrophic Lateral Sclerosis / therapy*
  • Cyanobacteria / chemistry
  • Cyanobacteria / physiology*
  • Enzyme Inhibitors / therapeutic use
  • Hair / chemistry
  • Humans
  • Neurotoxins / analysis
  • Neurotoxins / metabolism
  • Neurotoxins / toxicity*
  • Protein Transport / drug effects

Substances

  • Amino Acids
  • Amino Acids, Diamino
  • Amino Acids, Dicarboxylic
  • Enzyme Inhibitors
  • Neurotoxins
  • alpha-N-carboxy-beta-N-methylaminoalanine
  • Amino Acyl-tRNA Synthetases